ArticleNeuropsychiatric disease and treatment2025
Study on the Molecular Mechanism of Baicalin Phosphorylation of Tau Protein Content in a Cell Model of Intervention Cognitive Impairment.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural products and neurocognitive disorders: Mechanistic insights and research advances (Review).Molecular medicine reports · 2026Review
- Interferon regulatory factors: the next prospective targets for tissue ischemia-reperfusion injury?Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to predict the molecular mechanism of baicalein through network pharmacology, cell experiments and molecular docking. The goal was to elucidate the mechanism for the treatment of mild cognitive impairment. Materials and Methods: The protein-protein interaction network (PPI) and Cytoscape software were used to screen the hub genes of intersection genes, while the therapeutic mechanism of baicalein was predicted through the Gene ontology (GO) and Kyoto Encyclopedia of Gene and Genomes (KEGG) enrichment analysis. Molecular docking of the core target and baicalein was conducted using AutoDock software. The neuroprotective effect of Baicalein with different concentrations on okadaic acid-treated SH-SY5Y cells was investigated in cell experiments. Scratch experiments were conducted to explore the effect of baicalein on cell migration ability, and enzyme linked immunosorbent assay was employed to measure the content of extracellular pathological proteins. Western Blot and Cellular immunofluorescence pinpointed differences in the relevant protein content. Results: Enrichment analysis revealed significant enrichment in the PI3K-Akt signaling pathway, and molecular docking demonstrated a favorable binding energy between baicalein and AKT1. In cell experiments, baicalein presented a positive impact on mild cognitive impairment by elevating P-AKT1 and P-GSK-3β levels while reducing the overall amount of P-tau. Conclusion: As demonstrated by the present study, the low concentration of baicalein (15μmol/L) effectively managed the mild cognitive impairment by regulating the phosphorylation of AKT1 and GSK-3β.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.